639 reports of this reaction
4.5% of all DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE reports
#2 most reported adverse reaction
OCULAR HYPERAEMIA is the #2 most commonly reported adverse reaction for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, manufactured by Thea Pharma Inc.. There are 639 FDA adverse event reports linking DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE to OCULAR HYPERAEMIA. This represents approximately 4.5% of all 14,333 adverse event reports for this drug.
Patients taking DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE who experience ocular hyperaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OCULAR HYPERAEMIA is moderately reported among DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE users, representing a notable but not dominant share of adverse events.
In addition to ocular hyperaemia, the following adverse reactions have been reported for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE:
The following drugs have also been linked to ocular hyperaemia in FDA adverse event reports:
OCULAR HYPERAEMIA has been reported as an adverse event in 639 FDA reports for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OCULAR HYPERAEMIA accounts for approximately 4.5% of all adverse event reports for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, making it one of the most commonly reported side effect.
If you experience ocular hyperaemia while taking DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.